NEW YORK – Illumina Ventures is seeking $300 million for a new investment fund, according to filing with the US Securities and Exchange Commission this week.
Nicholas Naclerio, founding partner of Illumina Ventures, will manage the Illumina Innovation Fund III, which has yet to sell any shares, the document said.
Illumina Ventures, which invests in genomics and precision health startups, raised $230 million for its first fund in 2017. Its portfolio includes Arima Genomics, Broken String Biosciences, Delfi Diagnostics, DNAScript, Stilla Technologies, Tagomics, and Twist Bioscience.
The investment company took over Illumina’s genomics accelerator program last year.
Illumina recently acquired Fluent BioSciences, a single-cell sequencing startup that had also received investment from Illumina Ventures.